       Document 0703
 DOCN  M9630703
 TI    Naive CD4+ T cells confer idiotype-specific tumor resistance in the
       absence of antibodies.
 DT    9603
 AU    Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z;
       Lauritzsen GF; Institute of Immunology and Rheumatology, University of
       Oslo,; Norway.
 SO    Eur J Immunol. 1995 Nov;25(11):3079-86. Unique Identifier : AIDSLINE
       MED/96085179
 AB    CD4+ T cells can recognize a processed idiotypic peptide derived from
       the mouse lambda 2(315) immunoglobulin light chain. The idiotypic
       peptide is presented on the I-E(d) class II major histocompatibility
       complex molecule. Mice made transgenic for a lambda 2(315)-specific
       alpha beta T cell receptor have been demonstrated to be specifically
       resistant against a tumor challenge with the MOPC315 (alpha,lambda
       2(315)) plasmacytoma (Lauritzsen, G. F., Weiss, S., Dembic, Z. and
       Bogen, B., Proc. Natl. Acad. Sci. USA 1994, 91: 5700). That study,
       however, did not rule out a role of either anti-Id antibodies or T cells
       expressing nontransgenic specificities due to expression of endogenous T
       cell receptor (TcR) alpha chains. Also, the role of different T cell
       subsets in protection was unclear. To remove these ambiguities, we have
       now made the transgenic mice homozygous for the scid mutation, known to
       inhibit both Ig and TcR gene rearrangements. Such transgenic SCID mice
       lack B cells and antibodies while they still have plenty of CD4+ and
       CD4-8- cells expressing the transgenic alpha beta T cell receptor. The
       number of CD8+ T cell is dramatically reduced. Even so, transgenic SCID
       mice are protected against a challenge with MOPC315 plasmacytoma cells.
       Therefore, B cells, as well as novel T cell receptor specificities
       created by rearrangements of endogenous alpha-chain genes, are both
       dispensable for effective immunosurveillance in our system.
       Surprisingly, we found that transgenic CD8+ and CD4-8- cells are
       idiotype-specific and I-E(d) restricted. However, these T cell subsets
       are not required for resistance because adoptive transfer experiments
       demonstrated that highly purified transgenic SCID CD4+ cells suffice for
       tumor protection.
 DE    Animal  Antibodies, Anti-Idiotypic/*IMMUNOLOGY  CD4-Positive
       T-Lymphocytes/*IMMUNOLOGY  CD8-Positive T-Lymphocytes/IMMUNOLOGY  Female
       Gene Rearrangement, B-Lymphocyte/GENETICS  Gene Rearrangement,
       T-Lymphocyte/GENETICS  Immunoglobulins/BLOOD/GENETICS  Immunotherapy,
       Adoptive/METHODS  Lymphoid Tissue/IMMUNOLOGY  Male  Mice  Mice, Inbred
       BALB C  Mice, SCID  Mice, Transgenic  Neoplasm
       Transplantation/*IMMUNOLOGY  Neoplasms,
       Experimental/*IMMUNOLOGY/PREVENTION & CONTROL  Receptors, Antigen,
       T-Cell/GENETICS  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

